Viridian Therapeutics, Inc.
$19.31
Stock Quotes & Analysis
VRDN1.83%
$19.31
Latest AAPL News (Need to figure out how to make this dynamic)
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The ballots have been counted, the speeches have been made, and the confetti has settled.…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
Viridian Therapeutics, Inc.Status: Active
Sector: Healthcare
Industry: Biotechnology
Symbol: VRDN
Exchange: NCM
Employees: 94
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
 | 221 Crescent Street, Waltham, MA, United States |
 | 617 272 4600 |
 | https://www.viridiantherapeutics.com |